Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study.
Serum levels of soluble(s) interleukin-2 receptor (IL-2R), sCD4 and SCD8 were analysed in 227 melanoma patients, using a sandwich enzyme immunoassay. Different stages of the disease were considered, and a longitudinal study with a 2-year follow-up was performed. Mean values of sIL-2R were significantly higher than in normal controls in all stages and correlated with the disease progression. sCD8 increases with stage progression were less striking, while sCD4 values were always in the normal range. We conclude that sIL-2R measurement is a useful clinical parameter in monitoring disease evolution in melanoma.
Fierro
M T
MT
Clinica Dermatologica I, dell'Università di Torino, Italia.
Lisa
F
F
Novelli
M
M
Bertero
M
M
Bernengo
M G
MG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D015704:CD4 Antigens / Q000032:analysis*; D016827:CD8 Antigens / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008137:Longitudinal Studies; D008297:Male; D008545:Melanoma / Q000276:immunology*; D008875:Middle Aged; D009367:Neoplasm Staging; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012878:Skin Neoplasms / Q000276:immunology*
D014408:Biomarkers, Tumor; D015704:CD4 Antigens; D016827:CD8 Antigens; D015375:Receptors, Interleukin-2